Clostridium difficile
Day Zero Diagnostics Wins $300K SBIR Grant for Fecal Microbiota Transplant Assay
The Boston firm will develop a sequencing-based safety and efficacy assay for fecal microbiota transplants called epiXact FMT.
Diagenode already sells more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses for multiple infectious diseases.
ChromaCode Debuts Instrument-Agnostic Multiplex Panel for Multi-Drug Resistant Infection Screening
Premium
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.
Jun 27, 2019
Immunodiagnostics Firm Singulex Shutters Abruptly
May 14, 2019
Mobidiag Secures €25M Loan to Build Test Menu
May 2, 2019
Nov 28, 2018
Nov 8, 2018
Meridian Bioscience Q4 Revenues Grow 7 Percent
Oct 23, 2018
GenePOC C. Diff MDx Approved in Canada
Jul 31, 2018
Meridian Bioscience Q3 Revenues Grow 3 Percent
Jun 19, 2018
Apr 24, 2018
Nov 28, 2017
GenePOC C. Diff Test Receives FDA Approval
Nov 27, 2017